Condition (MeSH)
Carcinoid Tumor
ClinicalTrials.gov lists 104 trials for Carcinoid Tumor or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
100 of the 104 trials are tagged with Carcinoid Tumor itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoid Tumor trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 7 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 5 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 54 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoid Tumor trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 15 |
| Phase 1/2 | 7 |
| Phase 2 | 39 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Phase 4 | 2 |
| Not applicable | 5 |
| Observational | 22 |
| Expanded access | 3 |
How many Carcinoid Tumor trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 10 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 8 |
| Completed | 48 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoid Tumor trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Crinetics Pharmaceuticals Inc. | 2 |
| Ipsen | 2 |
| RayzeBio, Inc. | 2 |
Which drugs are being tested for Carcinoid Tumor? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 9 |
| NIVOLUMAB | 3 |
| Cabozantinib S-malate | 3 |
| "Capecitabine" | 2 |
| Telotristat Ethyl | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LAR Lanreotide | 5 |
| LAR Octreotide | 4 |
| 68Ga-DOTATOC PET/CT | 4 |
| Pasireotide s.c. | 4 |
| Sunitinib 4/2 | 3 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoid Tumor trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 67 | 15 |
| Pneumonia | 38 | 7 |
| Vomiting | 36 | 12 |
| Dehydration | 29 | 9 |
| Diarrhoea | 29 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoid Tumor? (99)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Performance of capsule endoscopy for the detection of small intestinal neuroendocrine tumors in familial carcinoid: a prospective single-site study. | Gastrointestinal endoscopy | 2024 | Yes |
| Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. | Neuroendocrinology | 2023 | Yes |
| Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. | Nature communications | 2023 | Yes |
| Controversies in appendiceal pathology: mucinous and goblet cell neoplasms. | Pathology | 2022 | Yes |
| MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. | The Journal of clinical endocrinology and metabolism | 2022 | Yes |
Showing 5 of 99 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.